Book chapter · 2011 · Open access

The Medicinal Value of Biodiversity: New Hits to Fight Cancer

Z. Giselle, Ana Carolina Santos de Souza, Angelo de, Matheus de Freitas Fernandes‐Pedrosa, V. Carmen, Hugo A. O. Roch

InTech eBooks · Published 14 November 2011 · DOI 10.5772/24599

Free PDFView at the publisherCite this paper

In brief

“The Medicinal Value of Biodiversity: New Hits to Fight Cancer” is a 2011 book chapter by Z. Giselle and 5 co-authors, published in InTech eBooks. OpenAlex counts 2 citations as of 15 November 2026. It is open access under a CC BY licence: the full text is free to read at InTech eBooks.

Citations
2
Most cited in
2017 (1)
References
199
Authors
6

Abstract

Natural products are produced by a wide range of different organisms. Microorganisms, plants, marine species, and animals employ such compounds for several purposes such as building blocks, coenzymes and cofactors, host-defense against microbial infection and predators, protection of ecological niches, communication between and within species, pigments, cellular signaling, gene expression, and homeostasis maintenance. Currently, many key therapeutic classes of drugs in use are derived from natural products, such as the antimalarial drug artemisinin, several anticancer agents, the lipid-lowering statins and immunosuppressors used to prevent the rejection of tissue grafts (Harvey, 2010). Since ancient times, natural products represent the main source of compounds employed in drug discovery and development. Still now, nature provides the mankind with a diversity of small bioactive compounds, opening promising avenues for the treatment of a great variety of diseases. Indeed, through millions of years, natural products have evolved to encompass a broad spectrum of chemical and functional diversity that enables them to target of a nearly limitless number of biological macromolecules in a highly selective manner. In contrast, synthetic molecules generated by combinatorial chemistry show lower chemical diversity and selective action than their natural counterparts. Because of these characteristics, natural products, mostly plant secondary metabolites, have seen great success as therapeutic agents. In fact, about 50% of the drugs introduced in the market during the last 20 years were derived directly or indirectly from bioactive compounds. Interestingly, of the approximately 1,200 new medicines approved by the FDA in the 25-year period up to 2006, only around one-third of the small molecules were completely synthetic in origin, with the remaining being natural products, direct derivatives of natural products or synthetic compounds inspired by a natural product lead (Vuorelaa et al., 2004; Newman & Cragg, 2009; Harvey, 2010). Besides the known diversity of bioactive compounds, it is certain that a great number of novel nature-based molecular structural models, with novel biological activities, remain to be discovered. It is currently estimated that approximately 420,000 plant species exist in

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Giselle, Z., de Souza, A. C. S., de, A., Fernandes‐Pedrosa, M. D. F., Carmen, V., & Roch, H. A. O. (2011). The Medicinal Value of Biodiversity: New Hits to Fight Cancer. InTech eBooks. https://doi.org/10.5772/24599

MLA 9

Giselle, Z., et al. “The Medicinal Value of Biodiversity: New Hits to Fight Cancer.” InTech eBooks, 2011. https://doi.org/10.5772/24599.

Chicago

Giselle, Z., Ana Carolina Santos de Souza, Angelo de, Matheus de Freitas Fernandes‐Pedrosa, V. Carmen, and Hugo A. O. Roch. 2011. “The Medicinal Value of Biodiversity: New Hits to Fight Cancer.” InTech eBooks. https://doi.org/10.5772/24599.

Harvard

Giselle, Z. et al. (2011) ‘The Medicinal Value of Biodiversity: New Hits to Fight Cancer’, InTech eBooks. doi:10.5772/24599.

IEEE

Z. Giselle, A. C. S. de Souza, A. de, M. D. F. Fernandes‐Pedrosa, V. Carmen, and H. A. O. Roch, “The Medicinal Value of Biodiversity: New Hits to Fight Cancer,” InTech eBooks, 2011, doi: 10.5772/24599.

BibTeX

@incollection{giselle2011medicinal,
  title     = {{The Medicinal Value of Biodiversity: New Hits to Fight Cancer}},
  author    = {Giselle, Z. and de Souza, Ana Carolina Santos and de, Angelo and Fernandes‐Pedrosa, Matheus de Freitas and Carmen, V. and Roch, Hugo A. O.},
  booktitle = {InTech eBooks},
  year      = {2011},
  doi       = {10.5772/24599},
  url       = {https://doi.org/10.5772/24599}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Bioactive natural compounds

  • natural products
  • biodiversity
  • anticancer agents
  • plant secondary metabolites
  • drug discovery
  • bioactive compounds
  • natural product-derived drugs
  • chemical diversity

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

Giselle, Z., de Souza, A. C. S., de, A., Fernandes‐Pedrosa, M. D. F., Carmen, V., & Roch, H. A. O. (2011). The Medicinal Value of Biodiversity: New Hits to Fight Cancer. InTech eBooks. https://doi.org/10.5772/24599

How many times has this paper been cited?

2 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at InTech eBooks.

Who wrote this paper?

Z. Giselle, Ana Carolina Santos de Souza, Angelo de, Matheus de Freitas Fernandes‐Pedrosa, V. Carmen, Hugo A. O. Roch.

What is the DOI of this paper?

10.5772/24599. The permanent link is https://doi.org/10.5772/24599.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.